Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 10770.0
(0.19%)
KRW 10770.0
(0.19%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 32.43 Million KRW | -22.22% |
| 2022 | 41.69 Million KRW | -62.46% |
| 2021 | 111.08 Million KRW | -99.62% |
| 2020 | 29.11 Billion KRW | 2718.2% |
| 2019 | 1.03 Billion KRW | -32.62% |
| 2018 | 1.53 Billion KRW | 4546.86% |
| 2017 | 32.98 Million KRW | -99.53% |
| 2016 | 7.04 Billion KRW | -17.12% |
| 2015 | 8.5 Billion KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - KRW | 0.0% |
| 2024 Q1 | 24.15 Million KRW | 0.0% |
| 2023 Q4 | 32.43 Million KRW | -85.12% |
| 2023 FY | 32.43 Million KRW | -22.22% |
| 2023 Q1 | 32.98 Million KRW | -20.88% |
| 2023 Q2 | 32.98 Million KRW | 0.0% |
| 2023 Q3 | 217.93 Million KRW | 560.62% |
| 2022 Q4 | 41.69 Million KRW | -35.79% |
| 2022 Q1 | 27.77 Million KRW | -75.0% |
| 2022 Q2 | 26.42 Million KRW | -4.84% |
| 2022 Q3 | 64.94 Million KRW | 145.75% |
| 2022 FY | 41.69 Million KRW | -62.46% |
| 2021 Q3 | 319.38 Million KRW | -39.48% |
| 2021 FY | 111.08 Million KRW | -99.62% |
| 2021 Q1 | 29.73 Billion KRW | 0.67% |
| 2021 Q2 | 527.72 Million KRW | -98.23% |
| 2021 Q4 | 111.08 Million KRW | -65.22% |
| 2020 Q4 | 29.53 Billion KRW | 7.47% |
| 2020 FY | 29.11 Billion KRW | 2718.2% |
| 2020 Q2 | 1.41 Billion KRW | 46.74% |
| 2020 Q1 | 961.54 Million KRW | -11.46% |
| 2020 Q3 | 27.48 Billion KRW | 1847.75% |
| 2019 Q3 | 1.24 Billion KRW | -13.45% |
| 2019 FY | 1.03 Billion KRW | -32.62% |
| 2019 Q4 | 1.08 Billion KRW | -12.76% |
| 2019 Q2 | 1.43 Billion KRW | -81.47% |
| 2019 Q1 | 7.76 Billion KRW | 372.28% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | 1.53 Billion KRW | 4546.86% |
| 2018 Q4 | 1.64 Billion KRW | -13.93% |
| 2018 Q3 | 1.9 Billion KRW | -1.64% |
| 2018 Q2 | 1.94 Billion KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 FY | 32.98 Million KRW | -99.53% |
| 2017 Q1 | 7.16 Billion KRW | 2.11% |
| 2017 Q2 | - KRW | -100.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2016 FY | 7.04 Billion KRW | -17.12% |
| 2016 Q2 | 11.47 Billion KRW | 32.61% |
| 2016 Q3 | 18.59 Billion KRW | 61.99% |
| 2016 Q4 | 7.01 Billion KRW | -62.28% |
| 2016 Q1 | 8.65 Billion KRW | 2.2% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q4 | 8.46 Billion KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 FY | 8.5 Billion KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 16 Billion KRW | 99.797% |
| ST Pharm Co.,Ltd. | 159.68 Billion KRW | 99.98% |
| ABL Bio Inc. | 43 Billion KRW | 99.925% |
| Cellid, Co., Ltd. | 6.48 Billion KRW | 99.5% |